Metabonomic Profiling of Serum and Urine by .sup.1H NMR-Based Spectroscopy Discriminates Patients with Chronic Obstructive Pulmonary Disease and Healthy Individuals

• Published in: PloS one 2013-06, Vol.8 (6), p.e65675
• Main Authors: Wang, Lingling, Tang, Yufu, Liu, Shuo, Mao, Shitao, Ling, Yuan, Liu, Dan, He, Xiaoyu, Wang, Xiaoge
• Format: Article
• Language: English
• Subjects: Branched chain amino acids; Chronic obstructive lung disease; Information management; Lactates; Magnetic resonance imaging; Medical research; Nuclear magnetic resonance spectroscopy
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0065675

Chronic obstructive pulmonary disease (COPD) has seriously impacted the health of individuals and populations. In this study, proton nuclear magnetic resonance (.sup.1 H NMR)-based metabonomics combined with multivariate pattern recognition analysis was applied to investigate the metabolic signatures of patients with COPD. Serum and urine samples were collected from COPD patients (n = 32) and healthy controls (n = 21), respectively. Samples were analyzed by high resolution .sup.1 H NMR (600 MHz), and the obtained spectral profiles were then subjected to multivariate data analysis. Consistent metabolic differences have been found in serum as well as in urine samples from COPD patients and healthy controls. Compared to healthy controls, COPD patients displayed decreased lipoprotein and amino acids, including branched-chain amino acids (BCAAs), and increased glycerolphosphocholine in serum. Moreover, metabolic differences in urine were more significant than in serum. Decreased urinary 1-methylnicotinamide, creatinine and lactate have been discovered in COPD patients in comparison with healthy controls. Conversely, acetate, ketone bodies, carnosine, m-hydroxyphenylacetate, phenylacetyglycine, pyruvate and [alpha]-ketoglutarate exhibited enhanced expression levels in COPD patients relative to healthy subjects. Our results illustrate the potential application of NMR-based metabonomics in early diagnosis and understanding the mechanisms of COPD.